Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.

Abstract

The proportion of HCV-infected patients over age 65years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12weeks in HCV genotype 1-infected patients with cirrhosis. Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were ≥65years of age. Sustained virological response at 12weeks (SVR12) was achieved by 94.2% (129/137) of those aged <65years and 97.7% (130/133) of those ≥65years. Diabetes was the most common comorbidity in patients ≥65years compared to younger patients (26.3% vs 12.4% P<.003). The most common adverse event (AE) in elderly patients was a grade 2 anaemia (35.3% vs 19.9% P<.004). Sofosbuvir/simeprevir plus a daily flat dose of RBV 800mg for 12weeks was highly effective and safe in genotype 1 elderly patients with compensated cirrhosis.